Insulet Appoints Former IDEXX CEO Jonathan Mazelsky to Board of Directors
PODD is trading near its 52-week low of $138.79 (7.3% above the low).
Summary
Insulet Corporation has appointed Jonathan J. Mazelsky, former President and CEO of IDEXX Laboratories, Inc., as a new independent director to its Board, effective July 1, 2026. His extensive experience in the healthcare and medical device sectors is expected to strengthen the board.
Key Events · Executive and Board Changes · PODD
-
New Director Appointment
Jonathan J. Mazelsky has been appointed as a Class II independent director to Insulet's Board of Directors, effective July 1, 2026.
-
Experienced Leadership
Mr. Mazelsky previously served as President and CEO of IDEXX Laboratories, Inc., where he oversaw significant revenue and stock price growth. He also held leadership roles at Philips Healthcare, Agilent Technologies, and Hewlett Packard, bringing extensive experience in medical devices and healthcare.
-
Director Compensation
As a non-employee director, Mr. Mazelsky will receive an initial grant of restricted stock units with a fair value of $216,548, representing a pro-rated annual award, along with cash compensation.
Analysis · PODD · Industrial Applications And Services
The appointment of Jonathan J. Mazelsky, a seasoned executive with a strong track record as CEO of IDEXX Laboratories, Inc., brings valuable leadership and industry expertise to Insulet's board. His background in medical devices and animal health diagnostics aligns well with Insulet's focus on diabetes management technology, potentially contributing to strategic growth and innovation. This move strengthens corporate governance and signals a commitment to experienced oversight.
At the time of this filing, PODD was trading at $148.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $10.3B. The 52-week trading range was $138.79 to $354.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.